Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases-Reference-Cited by-同舟云学术

Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases

Published:2015-06-17 Issue:7 Volume:11 Page:1748-1753
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Narayana Ashwath,Manoharan Aravind,Narayan Madhusudana Shampur,Kalappa Sudarshan Mysore,Biligumba Gangaboraiah,Haradanahalli Ravish,Anand Ashwini Manoor

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/21645515.2015.1048938

Reference20 articles.

1. WHO Expert Consultation on Rabies. Second report. Technical Report Series No. 982. Geneva: World Health Organization; 2013

2. WHO Expert Committee on Rabies. Eight report. Technical report series No. 824. Geneva: World Health Organization; 1992.

3. Failures of post-exposure rabies prophylaxis

4. Postexposure Rabies Prophylaxis Completed in 1 Week: Preliminary Study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterologous vaccination, from rabies vaccine to COVID-19 vaccine: View in clinical surgery;Formosan Journal of Surgery;2023-07-17

2. Lyssaviruses and Rabies Vaccines;Plotkin's Vaccines;2023

3. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study;Vaccine;2022-08

4. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety;Vaccine;2022-08

5. Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phase II pre-exposure prophylaxis regimen study;Vaccine;2022-08